Molecular Templates, Inc.

64 articles with Molecular Templates, Inc.

• Molecular Templates Provides Corporate Update and Outlines 2022 Milestones

  11/30/2021

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, provided a corporate update and outlined expected 2022 milestones.

• Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402

  11/18/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1.

• Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results

  11/15/2021

  Molecular Templates, Inc. today reported financial results for the third quarter of 2021.

• Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/20/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, will present and participate in 1-on-1 investor meetings at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

• Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

  8/12/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021.

• Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

  7/9/2021

  Molecular Templates, Inc. today announced the dosing of the first subject in a Phase 1 study investigating MT-6402 in patients with PD-L1-positive solid tumors.

• Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference

  7/6/2021

  Molecular Templates, Inc. announced that it will provide a corporate update and participate in 1-on-1 investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to take place July 13-14, 2021.

• Molecular Templates, Inc. Reports First Quarter 2021 Financial Results

  5/13/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2021.

• Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting

  4/12/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported that three posters featuring data on its pipeline programs and technology platform will be presented at the  AACR Virtual Annual Meeting I , taking place April 10-15, 2021.

• Molecular Templates to Prioritize Next-Generation ETB Candidates

  4/5/2021

  Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

• Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results

  3/18/2021

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2020.

• Molecular Templates to Participate in Upcoming Virtual Investor Conferences - Feb 26, 2021

  2/26/2021

  Molecular Templates, Inc. announced that it will present and participate in 1-on-1 investor meetings at the Cowen 41st Annual Health Care Conference, the Barclays Global Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference.

• Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering

  2/18/2021

  Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $12.65 per share.

• Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock

  2/17/2021

  Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it has commenced an underwritten public offering of its common stock.

• 

  Molecular Templates Forges Cancer Deal with BMS Worth up to $1.3 Billion

  2/12/2021

  Eric Poma, chief executive and scientific officer for Molecular Templates, touted the partnership with BMS and its strong oncology franchise.

• Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology

  1/19/2021

  Dosing in Phase 1 Study in Subjects with PD-L1-Positive Cancers Expected to Start in 2Q21

• Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

  12/21/2020

  Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is Reached

• Molecular Templates to Participate in Upcoming Virtual Investor Conferences

  11/16/2020

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will deliver presentations and participate in 1on1 meetings at the Stifel 2020 Virtual Healthcare Conference

• Molecular Templates, Inc. Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

  11/5/2020

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, reported financial results for the third quarter of 2020 and an update on its clinical pipeline.

• Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results

  8/6/2020

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2020.